Aurinia Pharmaceuticals Inc. AUPH
$16.25
▼ -0.19% 24H
About
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases that have high unmet medical needs. Its flagship product, LUPKYNIS (voclosporin), serves as the first FDA-approved oral therapy for adult patients with active lupus nephritis, a serious …
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryCanada
Employees128
TickerAUPH
Statistics
Market Cap$2.13B
Revenue (TTM)$283.1M
Net Income$287.2M
Net Margin101.5%
EPS$2.07
P/E7.34
P/S6.83
P/B3.65
EV/EBITDA11.09
ROE65.0%
Dividend Yield—
Price$16.25
Data: Twelve Data · Revenue = mcap / P/S